Family planning centers across the United States focused on telehealth and found creative ways to serve their clients after the COVID-19 pandemic rolled across North America in the winter and spring of 2020. Contraceptive Technology Update asked clinic leaders to participate in a Q&A about their operations during the pandemic.
In this double-blind, randomized controlled trial, etonogestrel implant users with prolonged or frequent menses who took 10 mg of tamoxifen twice daily for seven days as needed for irregular bleeding had an average of 9.8 (95% confidence interval, 4.6-15.0) more consecutive days of amenorrhea over a 90-day period compared to those who took a placebo.
The marathon race for finding an effective and safe male contraceptive has reached a hurdle that was not as much of a barrier for the research race to bring the first female contraceptive to market: Someone needs to prove men want their own contraceptive and will use whatever method succeeds.
Researchers across the world are studying hormonal and nonhormonal male contraceptive products in hopes of being the first to bring a new, reversible contraceptive for men to market within the next 10 to 20 years.
In this national retrospective cohort study of postpartum women, use of the etonogestrel contraceptive implant immediately postpartum was not associated with an increased rate of readmission for venous thromboembolism within 30 days of delivery.
In a model based on a national survey of 2,539 reproductive-age women in the United States, an over-the-counter, progestin-only contraceptive pill would appeal to 12.5 million adults and 1.75 million teens, assuming there were no out-of-pocket costs.
One of the challenges facing family planning clinics and obstetricians/gynecologists when serving transgender and gender-diverse patients is the lack of research and evidence-based guidelines to inform their clinical decisions. More research is needed about contraceptive needs and health effects on transgender and gender-diverse people, experts say.